Kaneka

Foam Molded Product made from KANEKA Biodegradable Polymer Green PlanetTM Adopted for Sony’s Large-screen TV Cushioning Material

Retrieved on: 
Monday, April 22, 2024
Recycling, Sustainability, Consumer Electronics, Technology, Other Manufacturing, Environment, Other Transport, Packaging, Green Technology, Chemicals, Plastics, Transport, Logistics, Supply Chain Management, Manufacturing, Corporation, Kaneka, Seawater, Water, Sony, Television, Petroleum, Plastic, Soil, BRAVIA, Multimedia, CO2, Kaneka Corporation

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii; hereinafter "Kaneka")(TOKYO:4118) has announced that its "Green Planet foam molded product" using KANEKA Biodegradable Polymer Green PlanetTM (hereinafter "Green Planet") has been adopted by Sony Corporation (Headquarters: Minato-ku, Tokyo; hereinafter "Sony") as a cushioning material for its large-screen televisions.

Key Points: 
  • Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii; hereinafter "Kaneka")(TOKYO:4118) has announced that its "Green Planet foam molded product" using KANEKA Biodegradable Polymer Green PlanetTM (hereinafter "Green Planet") has been adopted by Sony Corporation (Headquarters: Minato-ku, Tokyo; hereinafter "Sony") as a cushioning material for its large-screen televisions.
  • To ensure shock resistance for large, heavy televisions during transportation, a certain level of strength and durability is required.
  • Using Sony's technical expertise in packaging design and Kaneka's material molding technology, the two companies conducted a series of technical verifications to realize the use of Green Planet's foam molded product as cushioning materials.
  • This is a world first*2 for Green Planet foam molded products to be used as cushioning materials for home electric appliances.

Kaneka Acquires Japan Medical Device Technology

Retrieved on: 
Wednesday, December 6, 2023
Surgery, Medical Devices, Health, Cardiology, Medical Supplies, Atherosclerosis, Human body, Restenosis, Kaneka, Research, Biliary tract, Artery, Extremities, Esophagus, Metal, Sirolimus, Coronary artery disease, Risk, Corporation, Multimedia, FIH, Duodenum, Thrombosis, Blood, Human, Trachea, Kaneka Corporation, Pharmaceutical industry

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has acquired all shares of Japan Medical Device Technology Co., Ltd. (Headquarters: Kamimashiki-gun, Kumamoto; President: Shuzo Yamashita) (hereinafter JMDT), a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary.

Key Points: 
  • Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has acquired all shares of Japan Medical Device Technology Co., Ltd. (Headquarters: Kamimashiki-gun, Kumamoto; President: Shuzo Yamashita) (hereinafter JMDT), a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary.
  • In particular, stenting*1 for the treatment of coronary artery diseases such as atherosclerosis has a market worth 30 billion yen in Japan, and Kaneka is aiming to expand its business in this area.
  • It is a medical device that widens tubular parts of the human body (blood vessels, trachea, esophagus, duodenum, colon, biliary tract, etc.)
  • [Japan Medical Device Technology Co., Ltd.]

Kaneka Files Patent Infringement Lawsuit Against CoCrystal

Retrieved on: 
Monday, October 9, 2023
Patent, District court, Cocrystal, Q10, Crystal, Kaneka

TOKYO, Oct. 9, 2023 /PRNewswire/ -- On October 5, 2023, Kaneka Corporation filed a lawsuit in the United States District Court for the Eastern District of New York against Cocrystal Technology Co. Ltd. and Cocrystal Health Industry Co. Ltd. (collectively "CoCrystal") seeking an injunction and monetary damages for CoCrystal's infringement of Kaneka's U.S. Patent No.

Key Points: 
  • TOKYO, Oct. 9, 2023 /PRNewswire/ -- On October 5, 2023, Kaneka Corporation filed a lawsuit in the United States District Court for the Eastern District of New York against Cocrystal Technology Co. Ltd. and Cocrystal Health Industry Co. Ltd. (collectively "CoCrystal") seeking an injunction and monetary damages for CoCrystal's infringement of Kaneka's U.S. Patent No.
  • Kaneka asserts that CoCrystal uses Kaneka's patented production process to manufacture Crystal QH (the "Accused Product") in China, and then sells or offers to sell the Accused Product in the United States.
  • In the forthcoming lawsuit against CoCrystal, Kaneka is fully prepared to assertively enforce its patent rights to the fullest extent.
  • This may involve taking legal action against these customers, which could include adding them as additional defendants in the lawsuit against CoCrystal or initiating separate legal proceedings to address their patent infringement.

Kaneka Files Patent Infringement Lawsuit Against CoCrystal

Retrieved on: 
Monday, October 9, 2023
Patent, Multimedia, District court, Cocrystal, Q10, Crystal, Kaneka

TOKYO, Oct. 9, 2023 /PRNewswire/ -- On October 5, 2023, Kaneka Corporation filed a lawsuit in the United States District Court for the Eastern District of New York against Cocrystal Technology Co. Ltd. and Cocrystal Health Industry Co. Ltd. (collectively "CoCrystal") seeking an injunction and monetary damages for CoCrystal's infringement of Kaneka's U.S. Patent No.

Key Points: 
  • TOKYO, Oct. 9, 2023 /PRNewswire/ -- On October 5, 2023, Kaneka Corporation filed a lawsuit in the United States District Court for the Eastern District of New York against Cocrystal Technology Co. Ltd. and Cocrystal Health Industry Co. Ltd. (collectively "CoCrystal") seeking an injunction and monetary damages for CoCrystal's infringement of Kaneka's U.S. Patent No.
  • Kaneka asserts that CoCrystal uses Kaneka's patented production process to manufacture Crystal QH (the "Accused Product") in China, and then sells or offers to sell the Accused Product in the United States.
  • In the forthcoming lawsuit against CoCrystal, Kaneka is fully prepared to assertively enforce its patent rights to the fullest extent.
  • This may involve taking legal action against these customers, which could include adding them as additional defendants in the lawsuit against CoCrystal or initiating separate legal proceedings to address their patent infringement.